NCT06870539View on ClinicalTrials.gov

Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

CompletedOBSERVATIONAL
Enrollment

49

Participants

Timeline

Start Date

March 7, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Cancer-related Cognitive DysfunctionCytomegaloviral InfectionFallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
Interventions
OTHER

Non-Interventional Study

Non-Interventional Study

Trial Locations (2)

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT06870539 - Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment | Biotech Hunter | Biotech Hunter